Key points are not available for this paper at this time.
As compared with interferon alfa, temsirolimus improved overall survival among patients with metastatic renal-cell carcinoma and a poor prognosis. The addition of temsirolimus to interferon did not improve survival. (ClinicalTrials.gov number, NCT00065468 ClinicalTrials.gov.).
Building similarity graph...
Analyzing shared references across papers
Loading...
Gary R. Hudes
Fox Chase Cancer Center
Michael A. Carducci
Rutgers, The State University of New Jersey
Piotr Tomczak
Poznan University of Medical Sciences
New England Journal of Medicine
University of California, Los Angeles
Memorial Sloan Kettering Cancer Center
McMaster University
Building similarity graph...
Analyzing shared references across papers
Loading...
Hudes et al. (Wed,) studied this question.
synapsesocial.com/papers/69d7c01a3b601d7be3ae2af0 — DOI: https://doi.org/10.1056/nejmoa066838